All News
MAXIMISE results in axial manifestations of PsA. SEC met primary phase 3b ASAS 20 endpoint after inadequate NSAID response. https://t.co/e1j03KOo1K #ACR19 @RheumNow abs#2880 https://t.co/UtSDJGAW2G
Dr. Rachel Tate uptoTate ( View Tweet)
The draft 2020 ACR #gout guidelines were presented at the last slot of the meeting. Big changes for ULT initiation #ACR19 @RheumNow [Slides attached] https://t.co/bHBzQ3xwX8
Philip Robinson philipcrobinson ( View Tweet)
“Health tech isn’t just the future, it is the present” - @gnayyar
Listen to the incredible Dr. Geeta Nayyar talk to us about health tech, and about her favorite sessions at #ACR19!
@RheumNow https://t.co/OcYBws7pFE
Kanika Monga, MD DrKanikaMonga ( View Tweet)
CAPS (cryopyrin-associated periodic syndrome) is a heterogeneous group of autoinflammatory conditions that causes intermittent fevers (typically after cold exposure), as well as an urticarial-like rash. #ACR19 @RheumNow
Jonathan Hausmann MD hausmannMD ( View Tweet)
Remission ever or sustained in RA is same on triple DMARDs Therapy bs biological Rx. From Swedish register. ?channeling bias ?differential access? Either way this supports triple therapy use as impt in RA #ACR #ACR19 @RheumNow Abstract 2908 https://t.co/T8fRPr5a2A
Janet Pope Janetbirdope ( View Tweet)
Haploinsufficiency 20 (HA20) is a newly-described autoinflammatory disease caused by mutations in TNFAIP3, encoding the NF-kB regulatory protein A20.
#ACR19 @RheumNow
Jonathan Hausmann MD hausmannMD ( View Tweet)
Gout guidelines Allopurinol over febuxostat, dose low &slowly increase, T2T for serum Uric acid. Only Febuxostat if allopurinol failure/hypersensitivity. Only if failing with flares &tophi use peguricase. flares: colchicine steroids or NSAIDs #ACR @RheumNow https://t.co/ec6bOs5Hxo
Janet Pope Janetbirdope ( View Tweet)
2020 DRAFT ACR #gout Clinical Guidelines strongly recommend setting a serum urate goal and an active strategy to reach that goal @RheumNow https://t.co/8A6iTJgRPJ
Gout Study Group GoutGroup ( View Tweet)
Tildrakizumab (TIL), anti–IL-23p19 monoclonal ab, superior to PBO in phase 2b trial results in PsA. https://t.co/i0vIEHD4hx #ACR19 @RheumNow abs#2878 https://t.co/OmlhZfGdJi
Dr. Rachel Tate uptoTate ( View Tweet)
What unmet needs are found by young rheumatologists in Latin America? —>The opportunity to conduct research, especially money and time. Dr. Toro Gutierrez #ACR19 @RheumNow
Jonathan Hausmann MD hausmannMD ( View Tweet)
30-day rehospitalization after primary TKA or THA more likely in RA pts vs OA pts. All-type infections, AKI, and mechanical complications most common. https://t.co/iwPn9lCLrT #ACR19 @RheumNow abs#2872 https://t.co/hRUCXOysme
Dr. Rachel Tate uptoTate ( View Tweet)
RheumNow's expanded coverage of the #ACR2019 annual meeting is sponsored in part by Horizon Therapeutics. All content chosen by RheumNow and its faculty.
Dr. John Cush RheumNow ( View Tweet)
Phase 2b Bimekizumab study results in PsA shows neutralizing IL 17F and IL 17A may be a new target for LDA/treatment. https://t.co/uHvkFJn5z7 #ACR19 @RheumNow abs#2881 https://t.co/2EfzmyxY4M
Dr. Rachel Tate uptoTate ( View Tweet)
Rilonacept may have a role in Tx of steroid-refractory recurrent idiopathic pericarditis abstr#2905 #ACR19 #cleclinicrheum @RheumNow @CleClinicMD
Cassandra Calabrese CCalabreseDO ( View Tweet)
Risankizumab (RZB), humanized IgG1 monoclonal antibody and selective IL23p19 inhibitor, superior to PBO in PsA. Initial phase 2 results. No new safety signals noted. https://t.co/Jv1zpcg5Zd
#ACR19 @RheumNow abs#2877
Dr. Rachel Tate uptoTate ( View Tweet)
Infections In out patients are increased as measured by antimicromial scripts with RA and TNFi use comparing popn controls and pre and post RA TNFi use in pan Iceland registry #ACR19 #ACR @RheumNow abstr 2873. Higher than controls pre &even more after TNFi https://t.co/SlkIPP9WsJ
Janet Pope Janetbirdope ( View Tweet)
A new MBDA-based CVD risk score looks promising, for accurately predicting CVD risk in RA pts, abstr#2350 @RheumNow #ACR19
Cassandra Calabrese CCalabreseDO ( View Tweet)
Do you think of cachexia in SLE? I didn't before this. Maybe I missed what it is as 50% of Hopkins lupus cohort have cachexia by 5 yrs. Mot my experience #ACR #ACR19 @RheumNow #SLE abstract 1567 https://t.co/7cAU9r7RJV
Janet Pope Janetbirdope ( View Tweet)
Continue or stop biologics for RA if pregnant? Abstr# 2292 and 2279 show increase in flares, GC use, if biologics stopped at time of positive pregnancy test @RheumNow #ACR19
Cassandra Calabrese CCalabreseDO ( View Tweet)
Icelandic study shows RA pts use more antimicrobials in the 2 yrs prior to TNFi tx and have increased use 2 yrs after tx. https://t.co/GyUdQT2NvD abs#2873 #ACR19 @RheumNow https://t.co/HKU2IOPwcw
Dr. Rachel Tate uptoTate ( View Tweet)